260 related articles for article (PubMed ID: 22786987)
1. Radiofrequency ablation of lung tumors: imaging features of the postablation zone.
Abtin FG; Eradat J; Gutierrez AJ; Lee C; Fishbein MC; Suh RD
Radiographics; 2012; 32(4):947-69. PubMed ID: 22786987
[TBL] [Abstract][Full Text] [Related]
2. Radiofrequency ablation of medically inoperable stage IA non-small cell lung cancer: are early posttreatment PET findings predictive of treatment outcome?
Yoo DC; Dupuy DE; Hillman SL; Fernando HC; Rilling WS; Shepard JA; Siegel BA
AJR Am J Roentgenol; 2011 Aug; 197(2):334-40. PubMed ID: 21785078
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findings.
Purandare NC; Rangarajan V; Shah SA; Sharma AR; Kulkarni SS; Kulkarni AV; Dua SG
Radiographics; 2011; 31(1):201-13. PubMed ID: 21257942
[TBL] [Abstract][Full Text] [Related]
4. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results.
Okuma T; Okamura T; Matsuoka T; Yamamoto A; Oyama Y; Toyoshima M; Koyama K; Inoue K; Nakamura K; Inoue Y
Ann Nucl Med; 2006 Feb; 20(2):115-21. PubMed ID: 16615420
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
6. Radiofrequency ablation of non-small-cell carcinoma of the lung under real-time FDG PET CT guidance.
Schoellnast H; Larson SM; Nehmeh SA; Carrasquillo JA; Thornton RH; Solomon SB
Cardiovasc Intervent Radiol; 2011 Feb; 34 Suppl 2():S182-5. PubMed ID: 20508937
[TBL] [Abstract][Full Text] [Related]
7. The Maximum standardized uptake value is more reliable than size measurement in early follow-up to evaluate potential pulmonary malignancies following radiofrequency ablation.
Alafate A; Shinya T; Okumura Y; Sato S; Hiraki T; Ishii H; Gobara H; Kato K; Fujiwara T; Miyoshi S; Kaji M; Kanazawa S
Acta Med Okayama; 2013; 67(2):105-12. PubMed ID: 23603927
[TBL] [Abstract][Full Text] [Related]
8. Role of PET/Computed Tomography in Radiofrequency Ablation for Malignant Pulmonary Tumors.
Higuchi M; Suzuki H; Gotoh M
PET Clin; 2016 Jan; 11(1):47-55. PubMed ID: 26590443
[TBL] [Abstract][Full Text] [Related]
9. Fluorodeoxyglucose positron emission tomography for detection of tumor recurrence following radiofrequency ablation in retrospective cohort of stage I lung cancer.
Wang Y; Lanuti M; Bernheim A; Shepard JO; Sharma A
Int J Hyperthermia; 2018; 35(1):1-8. PubMed ID: 29719997
[TBL] [Abstract][Full Text] [Related]
10. Increase in fluorodeoxyglucose positron emission tomography activity following complete radiofrequency ablation of lung tumors.
Sharma A; Lanuti M; He W; Palmer EL; Shepard JA; Digumarthy SR
J Comput Assist Tomogr; 2013; 37(1):9-14. PubMed ID: 23321827
[TBL] [Abstract][Full Text] [Related]
11. Radiofrequency ablation of advanced lung tumors: imaging features, local control, and follow-up protocol.
Wang Y; Li G; Li W; He X; Xu L
Int J Clin Exp Med; 2015; 8(10):18137-43. PubMed ID: 26770411
[TBL] [Abstract][Full Text] [Related]
12. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results.
Veit P; Antoch G; Stergar H; Bockisch A; Forsting M; Kuehl H
Eur Radiol; 2006 Jan; 16(1):80-7. PubMed ID: 15868122
[TBL] [Abstract][Full Text] [Related]
13. MRI and CT characteristics of successfully ablated renal masses: Imaging surveillance after radiofrequency ablation.
Davenport MS; Caoili EM; Cohan RH; Ellis JH; Higgins EJ; Willatt J; Fox GA
AJR Am J Roentgenol; 2009 Jun; 192(6):1571-8. PubMed ID: 19457820
[TBL] [Abstract][Full Text] [Related]
14. Early PET/CT after radiofrequency ablation in colorectal cancer liver metastases: is it useful?
Liu ZY; Chang ZH; Lu ZM; Guo QY
Chin Med J (Engl); 2010 Jul; 123(13):1690-4. PubMed ID: 20819630
[TBL] [Abstract][Full Text] [Related]
15. CT imaging findings of pulmonary neoplasms after treatment with radiofrequency ablation: results in 32 tumors.
Bojarski JD; Dupuy DE; Mayo-Smith WW
AJR Am J Roentgenol; 2005 Aug; 185(2):466-71. PubMed ID: 16037522
[TBL] [Abstract][Full Text] [Related]
16. Radiofrequency ablation for treatment of thyroid follicular neoplasm with low SUV in PET/CT study.
Lin WC; Tung YC; Chang YH; Luo SD; Chiang PL; Huang SC; Chen WC; Chou CK; Su YY; Chen WC; Chi SY; Baek JH
Int J Hyperthermia; 2021; 38(1):963-969. PubMed ID: 34154505
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of radiofrequency ablation therapy for thoracic malignancies with evaluation by FDG-PET.
Higuchi M; Honjo H; Shigihara T; Shishido F; Suzuki H; Gotoh M
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1957-63. PubMed ID: 24952227
[TBL] [Abstract][Full Text] [Related]
18. Dual time-point (18)F-FDG PET/CT to assess response to radiofrequency ablation of lung metastases.
Lafuente S; Fuster D; Arguis P; Granados U; Perlaza P; Paredes P; Vollmer I; Sánchez M; Lomeña F
Rev Esp Med Nucl Imagen Mol; 2016; 35(4):226-31. PubMed ID: 26848142
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of pattern classification 24 hours after radiofrequency ablation of liver metastases on CT and positron emission tomography/CT.
Vandenbroucke F; Vandemeulebroucke J; Ilsen B; Verdries D; Belsack D; Everaert H; Buls N; Ros PR; de Mey J
J Vasc Interv Radiol; 2014 Aug; 25(8):1240-9. PubMed ID: 24954606
[TBL] [Abstract][Full Text] [Related]
20. Unresectable pulmonary malignancies: CT-guided percutaneous radiofrequency ablation--preliminary results.
Suh RD; Wallace AB; Sheehan RE; Heinze SB; Goldin JG
Radiology; 2003 Dec; 229(3):821-9. PubMed ID: 14657317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
